Centessa Pharmaceuticals plc (CNTA)

Market Cap	598.05M
Revenue (ttm)	n/a
Net Income (ttm)	-172.65M
Shares Out	97.40M
EPS (ttm)	-1.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	34,963
Open	5.94
Previous Close	6.08
Day's Range	5.89 - 6.33
52-Week Range	3.00 - 8.65
Beta	1.27
Analysts	Buy
Price Target	9.00 (+46.58%)
Earnings Date	Nov 9, 2023

About CNTA

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 28, 2021
• Employees: 64
• Stock Exchange: NASDAQ
• Ticker Symbol: CNTA

Analyst Forecast

According to 6 analysts, the average rating for CNTA stock is "Buy." The 12-month stock price forecast is $9.0, which is an increase of 46.58% from the latest price.

Price Target

$9.0

(46.58% upside)

Analyst Consensus: Buy